Thanks for that BearDownAZ,

I like the highlighted-underlined part the best:

I've been noticing a lot of talk about the utility of widespread screening/testing for coronary artery calcium score (CACS) to identify patients most at risk for cardiovascular disease. There is also growing evidence that elevated serum alkaline phosphatase levels are positively associated with an elevated CACS. It will be great if BETonMACE confirms that apabetalone reduces alkaline phosphatase levels (pre-specified secondary endpoint) as previously shown in post-hoc of SUSTAIN/ASSURE. If so, the next question is whether apabetalone improves the CACS. Perphaps in addition to BETonRENAL, they can do a BETonCACS trial in patients with high baseline CACS? I wonder if the docs obtained a baseline CACS in the BETonMACE patients so that they can measure change in CACS between baseline and end of study in BETonMACE?